We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
+16.74%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
–
AUM
$538M
AUM Growth
+$46.1M
Cap. Flow
-$2.96M
Cap. Flow %
-0.55%
Top 10 Hldgs %
69.12%
Holding
28
New
6
Increased
5
Reduced
9
Closed
1

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$14.1M
2
GH icon
Guardant Health
GH
+$13.1M
3
EXAS
Exact Sciences
EXAS
+$7.65M
4
TXG icon
10x Genomics
TXG
+$5.93M
5
HOWL icon
Werewolf Therapeutics
HOWL
+$4.08M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$14.7M
2
IQV icon
IQVIA
IQV
+$12.1M
3
DHR icon
Danaher
DHR
+$10.8M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$10.5M
5
ADPT icon
Adaptive Biotechnologies
ADPT
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 97.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$46.4B
$57.9M 10.75%
632,714
-58,148
-8% -$4.37M
ICLR icon
2
Icon
ICLR
$12.9B
$50.3M 9.34%
149,590
-15,510
-9% -$4.57M
ILMN icon
3
Illumina
ILMN
$29B
$43.8M 8.13%
327,679
– –
UTHR icon
4
United Therapeutics
UTHR
$22.7B
$41.2M 7.66%
179,499
+8,661
+5% +$1.95M
DXCM icon
5
DexCom
DXCM
$33.2B
$39.5M 7.34%
284,918
-24,400
-8% -$3.07M
ARGX icon
6
argenx
ARGX
$54.2B
$33.3M 6.19%
84,590
– –
IQV icon
7
IQVIA
IQV
$40B
$30.8M 5.73%
121,895
-51,700
-30% -$12.1M
DHR icon
8
Danaher
DHR
$146B
$28.4M 5.27%
113,685
-44,100
-28% -$10.8M
INSP icon
9
Inspire Medical Systems
INSP
$1.73B
$26.2M 4.88%
122,203
+8,700
+8% +$1.71M
TMDX icon
10
Transmedics
TMDX
$3.05B
$20.6M 3.83%
278,655
-36,200
-11% -$2.98M
PRCT icon
11
Procept Biorobotics
PRCT
$1.26B
$16.7M 3.1%
337,218
– –
GH icon
12
Guardant Health
GH
$22.8B
$15.1M 2.8%
730,209
+610,100
+508% +$13.1M
FDMT icon
13
4D Molecular Therapeutics
FDMT
$572M
$14.7M 2.74%
462,911
+25,000
+6% +$638K
ISRG icon
14
Intuitive Surgical
ISRG
$138B
$14.2M 2.64%
35,590
-7,800
-18% -$2.95M
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.65B
$14M 2.6%
+299,700
New +$14.1M
CRSP icon
16
PUT
CRISPR Therapeutics
CRSP
$5.17B
$13.4M 2.49%
+197,000
New +$14.1M
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.79B
$13.4M 2.48%
103,256
-86,100
-45% -$10.5M
FUSN
18
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$12.4M 2.3%
579,769
– –
AGIO icon
19
Agios Pharmaceuticals
AGIO
$1.94B
$9.67M 1.8%
330,830
– –
EXAS
20
DELISTED
Exact Sciences
EXAS
$8.36M 1.55%
+121,000
New +$7.65M
PACB icon
21
Pacific Biosciences
PACB
$357M
$8.13M 1.51%
2,167,021
+644,300
+42% +$3.77M
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$29B
$7.23M 1.34%
48,356
-88,400
-65% -$14.7M
TXG icon
23
10x Genomics
TXG
$7.47B
$5.07M 0.94%
+135,059
New +$5.93M
HOWL icon
24
Werewolf Therapeutics
HOWL
$19M
$4.54M 0.84%
+700,000
New +$4.08M
VKTX icon
25
Viking Therapeutics
VKTX
$3.98B
$3.69M 0.69%
+45,000
New +$2M
1
2

Similar funds

PIFP
Partners in Financial Planning Salem, Virginia $603M AUM 12.72% 1-Year Est. Return
IECM
Intrinsic Edge Capital Management Chicago, Illinois $603M AUM 66.97% 1-Year Est. Return
ERWM
Elk River Wealth Management Denver, Colorado $602M AUM 22.77% 1-Year Est. Return
CIG
Capricorn Investment Group Palo Alto, California $602M AUM 165.22% 1-Year Est. Return
JHCP
Jackson Hole Capital Partners Tulsa, Oklahoma $605M AUM 22.77% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
OCAM
Onex Canada Asset Management Toronto, Ontario, Canada $601M AUM 15.16% 1-Year Est. Return

Eagle Health Investments's Q1 2024 Portfolio in Review

As of Q1 2024, Eagle Health Investments held 28 positions worth $538M, up 9.4% from $492M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Eagle Health Investments's Q1 2024 filing shows 6 new, 5 increased, 9 reduced and 1 closed positions. Its largest new stake was Ultragenyx Pharmaceutical: 299,700 shares worth $14M. The largest sale was Alnylam Pharmaceuticals, an estimated $14.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

  • Eagle Health Investments's largest Q1 2024 buy was Ultragenyx Pharmaceutical: 299,700 shares worth $14M.
  • Eagle Health Investments added most to Guardant Health in Q1 2024, an estimated $13.1M increase.
  • Eagle Health Investments's biggest Q1 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $14.7M.
  • Eagle Health Investments fully exited Adaptive Biotechnologies in Q1 2024, selling an estimated $5.95M.
  • Eagle Health Investments's ten largest holdings make up 69% of its $538M portfolio in Q1 2024.
  • Eagle Health Investments opened 6 new positions and closed 1 in Q1 2024.
  • Eagle Health Investments's portfolio value rose 9.4% quarter-over-quarter to $538M.

Based on Eagle Health Investments's 13F filing for Q1 2024, filed 14 May 2024.